Navigation Links
Revealed:Protein's role in preventing heart muscle growth leading to heart failure
Date:5/12/2014

Cardiovascular disease remains the number one cause of death in the Western world, with heart failure representing the fastest-growing subclass over the past decade. The stage that precedes heart failure in a significant number of cardiovascular diseases is pathological hypertrophy the growth of the heart muscle in an attempt to increase its output.

Not all hypertrophy is pathological; for example, during pregnancy or high physical exertion, the muscle of the heart grows but myocardial function remains normal. But when hypertrophy is excessive, prolonged and unbalanced, it becomes pathological, leading to heart failure and arrhythmias.

Now for the first time, researchers at the Hebrew University of Jerusalem's Faculty of Medicine have revealed how a protein called Erbin acts as a brake against this excessive and pathological growth of heart muscle. They also demonstrated that damage to this protein leads to excess growth of heart muscle, a decrease in function, and severe pathological growth of heart muscle.

The research was conducted by Ms. Inbal Rachmin as part of her doctoral thesis, under the supervision of Prof. Ehud Razin and Dr. Sagi Tshori at the Institute for Medical Research IsraelCanada in the Faculty of Medicine at the Hebrew University of Jerusalem. The study, "Erbin is a negative modulator of cardiac hypertrophy," was published in the Proceedings of the National Academy of Sciences (PNAS).

Ms. Rachmin detected a significant decrease in the expression of the protein Erbin in the heart tissue of patients suffering from heart failure. Moreover, the induction of hypertrophy in mice lacking Erbin led to the early death all of these mice, compared to only about 30 percent mortality observed in the control group. Histological examination showed that heart failure was the main reason for this.

This important research also has further implications in the area of breast cancer treatment. Erbin interacts with the receptor Her2/ErBb2, which is overexpressed in approximately 30% of breast cancers. The standard treatment in these cases is the use of Herceptin, an antibody to this receptor. Studies have shown that 5-10 percent of breast cancer patients who received this treatment together with chemotherapy have a significant decrease in heart function. The researchers describe a cardioprotective role for Erbin, which suggests it is a potential target for cardiac gene therapy.


'/>"/>

Contact: Dov Smith
dovs@savion.huji.ac.il
972-258-82844
The Hebrew University of Jerusalem
Source:Eurekalert

Related medicine news :

1. New clues found to preventing lung transplant rejection
2. National plan for preventing healthcare-associated infections shows progress
3. New study shows promise for preventing therapy resistance in tumor cells
4. LA BioMed study finds daily antibiotics most effective in preventing recurrent urinary tract infection
5. Preventing Outdoor Decks From Failing
6. UV Technologies, LLC, Makers of UV-Aid® Release Results of Study Showing Photo-Oxidation Technology Highly Effective in Preventing Colds, Flu, and Ear Infections
7. Life Insurance for Seniors and the Importance of Preventing Chronic Diseases
8. Tips for Preventing Kitchen Hassles Released in New Article from Apollo Plumbing
9. Top hospitals reduce readmissions by preventing complications across all diagnoses
10. Edoxaban effective in preventing stroke, reducing bleeding and cardiovascular death in patients with atrial fibrillation
11. Seven Helpful Tips For Preventing Back Pain In Those With Sedentary Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: